Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02713529 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer
A Phase 1 study, sponsored by AmMax Bio.
- Completed
- Registry status
- Phase 1
- Development phase
- 117
- Enrollment target
NCT02713529 is a Phase 1 study that has completed, run by AmMax Bio. The registered enrollment target is 117 participants.
The verdict
NCT02713529, a Phase 1 study, has completed, sponsored by AmMax Bio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 117 participants
- Enrollment target
Study Summary
A multi-center Phase 1b/2 study testing the combination of AMG 820 and pembrolizumab in subjects with select advanced solid tumors.
Interventions
- BIOLOGICAL AMG820 and pembrolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2016-04-14 |
| Est. Completion | 2019-05-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02713529
The ClinicalTrials.gov registry entry for NCT02713529 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 117 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AmMax Bio, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AMG820 and pembrolizumab is the first listed.
NCT02713529 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02713529 about?
NCT02713529 is a clinical study titled "Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer". A multi-center Phase 1b/2 study testing the combination of AMG 820 and pembrolizumab in subjects with select advanced solid tumors.
What is the current status of trial NCT02713529?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 117 participants. The study started on 2016-04-14. Estimated completion is 2019-05-17.
What interventions are being tested in trial NCT02713529?
The interventions under investigation include: AMG820 and pembrolizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02713529?
This trial is sponsored by AmMax Bio, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.